Therapeutic antibodies targeting "don't eat me" protein, such as CD47, demonstrates promising anti-tumor efficacy in preclinical models and in clinic. However, the clinical development of anti-CD47 mAbs that retain substantial FcR activating capacity (e.g. human IgG1) has been hampered by the ...